ArticleJournal of clinical medicine2019
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Guideline
- Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-ResistantGut and liver · 2026Trial
- Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-ResistantGut and liver · 2022Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Clinical Evaluation of a Stool-Based Molecular Point-of-Care Test Kit for Noninvasive Detection of Helicobacter pylori Infection and Clarithromycin Resistance.Canadian journal of gastroenterology & hepatology · 2026Article
- Prevalence and Variability ofAntibiotics (Basel, Switzerland) · 2025Article
- Analysis of antibiotic susceptibility and genomic characteristics of Helicobacter pylori by whole-genome resequencing in Northern China.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility ofGut and liver · 2023Article
- [Vonoprazan-based Dual and Triple Therapy forThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- [Evidence-based Therapy: A Rational Approach toThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- [Bismuth, An Indispensable Component ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Quantitative multiplex real-time polymerase chain reaction assay for the detection of Helicobacter pylori and clarithromycin resistance.BMC microbiology · 2023Article
- Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Article
- Current guidelines forWorld journal of clinical cases · 2022Review
- Study on the value of antibiotic-resistant gene detection inExperimental and therapeutic medicine · 2022Article
- Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment.Cancer cell international · 2021Article
- Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients withJournal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsClarithromycin resistance in
methodsA total of 431 adult patients with
resultsSequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C). The clarithromycin resistance rate was 21.3% in the overall group of patients. A2143G was the most clinically significant point mutation (84/431, 19.5%), while T2182C was the most clinically insignificant point mutation (283/431, 65.7%). The overall
conclusionsThere were significantly lower eradication rates in the patients with clarithromycin-resistant
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.